221 related articles for article (PubMed ID: 26232328)
1. Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.
Leoh LS; Daniels-Wells TR; Martínez-Maza O; Penichet ML
Mol Immunol; 2015 Oct; 67(2 Pt B):407-15. PubMed ID: 26232328
[TBL] [Abstract][Full Text] [Related]
2. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.
Hezareh M; Hessell AJ; Jensen RC; van de Winkel JG; Parren PW
J Virol; 2001 Dec; 75(24):12161-8. PubMed ID: 11711607
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.
Leoh LS; Kim YK; Candelaria PV; Martínez-Maza O; Daniels-Wells TR; Penichet ML
J Immunol; 2018 May; 200(10):3485-3494. PubMed ID: 29654211
[TBL] [Abstract][Full Text] [Related]
4. An IgG1 Version of the Anti-transferrin Receptor 1 Antibody ch128.1 Shows Significant Antitumor Activity Against Different Xenograft Models of Multiple Myeloma: A Brief Communication.
Daniels-Wells TR; Candelaria PV; Leoh LS; Nava M; Martínez-Maza O; Penichet ML
J Immunother; 2020; 43(2):48-52. PubMed ID: 31693515
[TBL] [Abstract][Full Text] [Related]
5. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
6. Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents.
Candelaria PV; Leoh LS; Penichet ML; Daniels-Wells TR
Front Immunol; 2021; 12():607692. PubMed ID: 33815364
[TBL] [Abstract][Full Text] [Related]
7. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
[TBL] [Abstract][Full Text] [Related]
8. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma.
Shimosaki S; Nakahata S; Ichikawa T; Kitanaka A; Kameda T; Hidaka T; Kubuki Y; Kurosawa G; Zhang L; Sudo Y; Shimoda K; Morishita K
Biochem Biophys Res Commun; 2017 Mar; 485(1):144-151. PubMed ID: 28189691
[TBL] [Abstract][Full Text] [Related]
9. A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions.
Neiveyans M; Melhem R; Arnoult C; Bourquard T; Jarlier M; Busson M; Laroche A; Cerutti M; Pugnière M; Ternant D; Gaborit N; Chardès T; Poupon A; Gouilleux-Gruart V; Pèlegrin A; Poul MA
MAbs; 2019 Apr; 11(3):593-605. PubMed ID: 30604643
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of an Anti-transferrin Receptor 1 Antibody Against AIDS-related Non-Hodgkin Lymphoma: A Brief Communication.
Daniels-Wells TR; Widney DP; Leoh LS; Martínez-Maza O; Penichet ML
J Immunother; 2015 Oct; 38(8):307-10. PubMed ID: 26325374
[TBL] [Abstract][Full Text] [Related]
11. The influence of the hinge region length in binding of human IgG to human Fcgamma receptors.
Redpath S; Michaelsen TE; Sandlie I; Clark MR
Hum Immunol; 1998 Nov; 59(11):720-7. PubMed ID: 9796740
[TBL] [Abstract][Full Text] [Related]
12. An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies.
Daniels TR; Ortiz-Sánchez E; Luria-Pérez R; Quintero R; Helguera G; Bonavida B; Martínez-Maza O; Penichet ML
J Immunother; 2011; 34(6):500-8. PubMed ID: 21654517
[TBL] [Abstract][Full Text] [Related]
13. Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region.
Michaelsen TE; Aase A; Norderhaug L; Sandlie I
Mol Immunol; 1992 Mar; 29(3):319-26. PubMed ID: 1557042
[TBL] [Abstract][Full Text] [Related]
14. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
15. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
17. IgG2m4, an engineered antibody isotype with reduced Fc function.
An Z; Forrest G; Moore R; Cukan M; Haytko P; Huang L; Vitelli S; Zhao JZ; Lu P; Hua J; Gibson CR; Harvey BR; Montgomery D; Zaller D; Wang F; Strohl W
MAbs; 2009; 1(6):572-9. PubMed ID: 20073128
[TBL] [Abstract][Full Text] [Related]
18. Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.
Lo M; Kim HS; Tong RK; Bainbridge TW; Vernes JM; Zhang Y; Lin YL; Chung S; Dennis MS; Zuchero YJ; Watts RJ; Couch JA; Meng YG; Atwal JK; Brezski RJ; Spiess C; Ernst JA
J Biol Chem; 2017 Mar; 292(9):3900-3908. PubMed ID: 28077575
[TBL] [Abstract][Full Text] [Related]
19. Targeting TfR1 with the ch128.1/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV
Martínez LE; Daniels-Wells TR; Guo Y; Magpantay LI; Candelaria PV; Penichet ML; Martínez-Maza O; Epeldegui M
Mol Cancer Ther; 2021 Sep; 20(9):1592-1602. PubMed ID: 34158342
[TBL] [Abstract][Full Text] [Related]
20. Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells.
Rodríguez JA; Luria-Pérez R; López-Valdés HE; Casero D; Daniels TR; Patel S; Avila D; Leuchter R; So S; Ortiz-Sánchez E; Bonavida B; Martínez-Maza O; Charles AC; Pellegrini M; Helguera G; Penichet ML
Leuk Lymphoma; 2011 Nov; 52(11):2169-78. PubMed ID: 21870996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
